Abstract
In the last few decades, glucocorticoids have received increasing attention for their capability of provoking systemic hypersensitivity reactions, when administered orally, parenterally, or intralesionally, as well as allergic skin and mucosal symptoms, when applied locally to the skin in patients with contact dermatitis or to the mucosa in patients with asthma and/or rhinitis. However, because of their anti-inflammatory and immunosuppressive properties, glucocorticoids are often not suspected of such hypersensitivity reactions. In addition, because glucocorticoids retain their antiinflammatory potential, even if they act as sensitizers, the signs and symptoms of allergic reactions are not always obvious, particularly when they overlap with those caused by the very diseases glucocorticoids are used to treat. Moreover, interpretation of diagnostic tests, specifically that of patch-test reactions, can be difficult. In this review, particular attention is addressed to the problem of allergenic cross-reactivity among topical and systemic glucocorticoids. We also look at the clinical and practical aspects of both cell-mediated and IgE-mediated hypersensitivity reactions to glucocorticoids and their consequences on anti-inflammatory therapeutic choices.
Keywords: Adverse drug reaction, Contact dermatitis, Cell-mediated-reaction, Cross-reactivity, Glucocorticosteroids, Hypersensitivity, IgE-mediated-reaction, Intradermal tests, Patch tests
Current Pharmaceutical Design
Title: Cross-Reactivity in Cell-Mediated and IgE-Mediated Hypersensitivity to Glucocorticoids
Volume: 12 Issue: 26
Author(s): M. T. Ventura, G. F. Calogiuri, L. Muratore, E. Di Leo, R. Buquicchio, A. Ferrannini, O. Resta and A. Romano
Affiliation:
Keywords: Adverse drug reaction, Contact dermatitis, Cell-mediated-reaction, Cross-reactivity, Glucocorticosteroids, Hypersensitivity, IgE-mediated-reaction, Intradermal tests, Patch tests
Abstract: In the last few decades, glucocorticoids have received increasing attention for their capability of provoking systemic hypersensitivity reactions, when administered orally, parenterally, or intralesionally, as well as allergic skin and mucosal symptoms, when applied locally to the skin in patients with contact dermatitis or to the mucosa in patients with asthma and/or rhinitis. However, because of their anti-inflammatory and immunosuppressive properties, glucocorticoids are often not suspected of such hypersensitivity reactions. In addition, because glucocorticoids retain their antiinflammatory potential, even if they act as sensitizers, the signs and symptoms of allergic reactions are not always obvious, particularly when they overlap with those caused by the very diseases glucocorticoids are used to treat. Moreover, interpretation of diagnostic tests, specifically that of patch-test reactions, can be difficult. In this review, particular attention is addressed to the problem of allergenic cross-reactivity among topical and systemic glucocorticoids. We also look at the clinical and practical aspects of both cell-mediated and IgE-mediated hypersensitivity reactions to glucocorticoids and their consequences on anti-inflammatory therapeutic choices.
Export Options
About this article
Cite this article as:
Ventura T. M., Calogiuri F. G., Muratore L., Di Leo E., Buquicchio R., Ferrannini A., Resta O. and Romano A., Cross-Reactivity in Cell-Mediated and IgE-Mediated Hypersensitivity to Glucocorticoids, Current Pharmaceutical Design 2006; 12 (26) . https://dx.doi.org/10.2174/138161206778194006
DOI https://dx.doi.org/10.2174/138161206778194006 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Aggressive Medical Approach for Inflammatory Bowel Disease: Clinical Challenges and Therapeutic Profiles in a Retrospective Hospitalbased Series
Current Clinical Pharmacology The Future of Post-Genomic Biology at the Proteomic Level: An Outlook
Combinatorial Chemistry & High Throughput Screening Anti-inflammatory Effects of Mesenchymal Stem Cells and their Secretomes in Pneumonia
Current Pharmaceutical Biotechnology Editorial: (Thematic Issue: Occupational Exposure: An Undermined Risk Factor of Lung Diseases in the Informal Sectors of Developing Economy)
Current Respiratory Medicine Reviews Aberrant Activation of Arachidonic Acid and Eicosanoid Pathways-Targets for Treating Prostate Cancer
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Aspirin Intolerance: Experimental Models for Bed-to-Bench
Current Drug Targets 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets Modulation of Mast Cell and Basophil Functions by Benzene Metabolites
Current Pharmaceutical Design Synthesis of Novel Benzoquinones with Anti-Inflammatory Activity
Letters in Drug Design & Discovery Dendritic Cells in Pathogenesis of COPD
Current Pharmaceutical Design DNA Methylation Markers in Lung Cancer
Current Genomics Advancements in Devices and Particle Engineering in Dry Powder Inhalation Technology
Current Topics in Medicinal Chemistry Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases
Current Medicinal Chemistry Emerging Anti-inflammatory Therapies for Atherosclerosis
Current Pharmaceutical Design Molecular and Cellular Mechanisms of Hexavalent Chromium-Induced Lung Cancer: An Updated Perspective
Current Drug Metabolism Respiratory Tract Manifestations of Rheumatic Diseases in Children
Current Respiratory Medicine Reviews Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol
Current Vascular Pharmacology Recent Patents on the Treatment of Type 1 Diabetes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Role of the New Zealand Intensive Medicines Monitoring Programme in Identification of Previously Unrecognised Signals of Adverse Drug Reactions
Current Drug Safety